XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Sep. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of changes in contract assets and liabilities

Fiscal year ended

September 30, 

2021

2020

Opening balance

    

$

1,879

    

$

2,119

Additions

 

6,985

 

2,511

Deductions

 

(2,670)

 

(2,751)

Ending balance

$

6,194

$

1,879

Fiscal year ended

September 30, 

2021

2020

Opening balance

    

$

11,392

    

$

6,726

Additions

 

208,377

 

106,956

Deductions

 

(193,155)

 

(102,290)

Ending balance

$

26,614

$

11,392

Summary of activity in allowance for doubtful accounts

Fiscal year ended September 30, 

    

2021

    

2020

Opening balance

$

561

$

1,759

Charged to expense

 

208

 

180

Uncollectible invoices written off

 

(77)

 

(1,378)

Amounts collected

 

(24)

 

Ending balance

$

668

$

561

Summary of activity in inventory obsolescence

Fiscal year ended September 30, 

2021

2020

Opening balance

    

$

177

    

$

198

Provision for slow moving and obsolescence

 

10

 

84

Write-off of obsolete and slow moving inventory

 

(47)

 

(105)

Closing balance

$

140

$

177

Schedule of property, plant and equipment, net

As of September 30, 

2021

    

2020

Land and improvements

$

2,276

$

1,755

Buildings and improvements

 

40,169

 

29,813

Machinery and equipment

 

36,743

 

27,500

Office furniture and fixtures

 

1,338

 

828

Construction in progress

 

3,725

 

718

 

84,251

 

60,614

Less: accumulated depreciation

 

(36,273)

 

(31,885)

Net property and equipment

$

47,978

$

28,729

Schedule of changes in goodwill

    

    

Goodwill

Balance as of October 1, 2019

$

3,617

Acquisition of PCRS

751

Balance as of September 30, 2020

$

4,368

Acquisition of HistoTox Labs

 

9,129

Acquisition of Bolder BioPATH

36,223

Acquisition of Gateway Laboratories

2,207

Balance as of September 30, 2021

$

51,927

Schedule of changes in the balances of intangible assets

    

Client

Non-Compete

    

    

    

    

Trademarks

    

Relationships

    

Agreements

    

Backlog

    

Patents

    

Totals

Balance as of October 1, 2019

$

1,072

$

1,670

$

131

$

$

10

$

2,883

Acquisition of PCRS

460

1,280

220

121

2,081

Amortization

 

(103)

 

(380)

 

(93)

 

(121)

 

(6)

 

(703)

Balance as of September 30, 2020

$

1,429

$

2,570

$

258

$

$

4

$

4,261

Acquisition of HistoTox Labs

 

6,800

1,700

8,500

Acquisition of Bolder BioPATH

12,500

12,500

Acquisition of BioReliance

640

640

Acquisition of Gateway Laboratories

100

100

Amortization

 

(109)

(1,413)

(244)

(2)

 

(1,768)

Balance as of September 30, 2021

$

1,320

$

21,197

$

1,714

$

$

2

$

24,233

Schedule of future amortization expense

Future amortization expense for intangible assets at September 30, 2021 for the next five years and a total, thereafter, are as follows:

2022

2023

2024

2025

2026

Thereafter

Totals

Trademarks

    

109

    

109

    

109

    

108

    

108

    

777

    

1,320

Client Relationships

 

2,913

2,913

 

2,912

 

2,912

 

2,851

 

6,696

 

21,197

Non-Compete Agreements

 

431

 

395

 

349

 

340

 

199

 

 

1,714

Patents

 

2

 

 

 

 

 

 

2

$

3,455

$

3,417

$

3,370

$

3,360

$

3,158

$

7,473

$

24,233

Summary of changes in the balances of the level three financial instruments

Contingent

Convertible

    

    

Consideration

    

Notes

    

Totals

Balance as of September 30, 2020

$

$

$

Contingent consideration related to BioReliance acquisition

640

640

Convertible senior notes

63,284

63,284

Fair value adjustment of convertible senior notes

(8,362)

(8,362)

Balance as of September 30, 2021

$

640

$

54,922

$

55,562